肺腺癌更新:组织学、细胞学与分级
本文阐述了2021年第五版WHO肺腺癌分类的依据,重点讨论非黏液性肿瘤的分级及活检/细胞学诊断。PubMed检索显示,腺癌分级系统改善了肺腺癌分类的预后影响,小活检中准确诊断腺癌对组织分流用于分子检测及患者管理至关重要。
要点
- 腺癌组织学模式与预后强相关,是分级系统的基础。
- 小活检中准确诊断腺癌对分子检测组织分流至关重要。
- 目前所有可靶向突变均在腺癌中发现,需精确分类指导治疗。
核心结论
- 腺癌分级系统改善了肺腺癌分类的预后影响。
- 小活检中准确诊断腺癌对组织分流用于分子研究及患者管理重要。
研究设计与样本
- 基于PubMed检索的综述,讨论2021年第五版WHO肺腺癌分类依据。
主要发现
- 腺癌组织学模式与预后强相关,构成分级系统基础。
- 所有可靶向突变迄今均在腺癌中发现。
临床怎么用
- 对小活检标本准确诊断腺癌,以分流组织进行分子检测。
- 依据组织学模式进行分级,辅助预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Adenocarcinomas are the most common histologic subtype of lung cancer, and exist within a widely divergent clinical, radiologic, molecular, and histologic spectrum. There is a strong association between histologic patterns and prognosis that served as the basis for a recently described grading system. As the study of molecular pathology rapidly evolves, all targetable mutations so far have been found in adenocarcinomas, thus requiring accurate diagnosis and classification for the triage of molecular alterations and adequate therapy. OBJECTIVE.—: To discuss the rationale for adenocarcinoma classifications within the 2021 5th edition of the World Health Organization Classification, with a focus on nonmucinous tumors, including tumor grading and biopsy/cytology diagnosis. DATA SOURCES.—: PubMed search. CONCLUSIONS.—: A grading system for adenocarcinoma has improved prognostic impact of the classification of pulmonary adenocarcinoma. An accurate diagnosis of adenocarcinoma in small biopsy material is important for tissue triage for molecular studies and ultimately for patient management and treatment.
引用
- Sharma J, Zhou F, Moreira AL, et al. Pulmonary Adenocarcinoma Updates: Histology, Cytology, and Grading. Arch Pathol Lab Med. 2025. PMID: 39667395. doi:10.5858/arpa.2023-0540-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。